APA (7th ed.) Citation

CD, L., W, B., M, D., M, R., LV, P., J, S., . . . B, F. (2019). Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget, 10(53), 5523. https://doi.org/10.18632/oncotarget.27148

Chicago Style (17th ed.) Citation

CD, Lowery, et al. "Anti-VEGFR2 Therapy Delays Growth of Preclinical Pediatric Tumor Models and Enhances Anti-tumor Activity of Chemotherapy." Oncotarget 10, no. 53 (2019): 5523. https://doi.org/10.18632/oncotarget.27148.

MLA (9th ed.) Citation

CD, Lowery, et al. "Anti-VEGFR2 Therapy Delays Growth of Preclinical Pediatric Tumor Models and Enhances Anti-tumor Activity of Chemotherapy." Oncotarget, vol. 10, no. 53, 2019, p. 5523, https://doi.org/10.18632/oncotarget.27148.